- Home
- HHH vs PTGX Comparison
HHH vs PTGX Comparison
Compare HHH & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HHH
- PTGX
- Stock Information
- Founded
- HHH 2010
- PTGX 2006
- Country
- HHH United States
- PTGX United States
- Employees
- HHH N/A
- PTGX N/A
- Industry
- HHH Real Estate Investment Trusts
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- HHH Real Estate
- PTGX Health Care
- Exchange
- HHH Nasdaq
- PTGX Nasdaq
- Market Cap
- HHH 3.3B
- PTGX 2.9B
- IPO Year
- HHH N/A
- PTGX 2016
- Fundamental
- Price
- HHH $66.96
- PTGX $55.06
- Analyst Decision
- HHH Buy
- PTGX Strong Buy
- Analyst Count
- HHH 2
- PTGX 9
- Target Price
- HHH $80.50
- PTGX $67.11
- AVG Volume (30 Days)
- HHH 479.5K
- PTGX 1.0M
- Earning Date
- HHH 07-25-2025
- PTGX 08-05-2025
- Dividend Yield
- HHH N/A
- PTGX N/A
- EPS Growth
- HHH N/A
- PTGX N/A
- EPS
- HHH 5.22
- PTGX 0.86
- Revenue
- HHH $1,793,533,000.00
- PTGX $207,801,000.00
- Revenue This Year
- HHH N/A
- PTGX N/A
- Revenue Next Year
- HHH $24.62
- PTGX $47.15
- P/E Ratio
- HHH $12.88
- PTGX $64.57
- Revenue Growth
- HHH 106.40
- PTGX N/A
- 52 Week Low
- HHH $59.83
- PTGX $32.50
- 52 Week High
- HHH $87.77
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- HHH 45.05
- PTGX 64.63
- Support Level
- HHH $65.72
- PTGX $52.16
- Resistance Level
- HHH $68.49
- PTGX $57.18
- Average True Range (ATR)
- HHH 1.55
- PTGX 1.85
- MACD
- HHH -0.29
- PTGX -0.27
- Stochastic Oscillator
- HHH 32.08
- PTGX 55.14
About HHH Howard Hughes Holdings Inc.
Howard Hughes Holdings Inc owns, manages, and develops commercial, residential, and mixed-use real estate throughout the USA. Its portfolio is strategically positioned to meet and accelerate development based on market demand, resulting in one of the strongest real estate platforms in the country. It operates through four business segments: Operating Assets, MPCs, Strategic Developments and Seaport.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.